AARE-Controlled Pro-Apoptotic Gene Expression for Cellular Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods lack a reliable, highly specific, and safe means to modulate transgene expression, and existing suicide systems for cellular therapies, such as CAR T-cell and iPSC-based treatments, face challenges like immunogenicity and slow activation, posing risks for adverse effects and tumorigenesis.
Innovation Solution
A nucleic acid-based system utilizing an Amino Acid Response Element (AARE) regulatory sequence to control the expression of a pro-apoptotic protein, activated by a diet deficient in essential amino acids, providing a rapid and safe 'suicide switch' for therapeutic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a suicide switch system is introduced into CAR T-cells or stem cells for safety, then adverse effects and tumorigenesis risks are reduced, but the system complexity and potential immunogenicity increase
Solution Approach 1:
The patent extracts the suicide switch function into a separate, independently controllable genetic module that can be activated or deactivated without affecting the primary therapeutic function of CAR T-cells or stem cells. This modular approach reduces system complexity by separating safety mechanisms from therapeutic mechanisms.
Solution Approach 2:
The patent introduces an intermediary small molecule inducer that mediates between the external environment and the pro-apoptotic protein expression. This intermediary allows precise temporal and spatial control of the suicide switch activation, reducing direct system complexity while maintaining safety functionality.
2Reliability
If a suicide switch system is introduced into CAR T-cells or stem cells for safety, then adverse effects and tumorigenesis risks are reduced, but immune response and adverse effects may increase due to foreign protein expression
Solution Approach 1:
The patent employs homogeneity by using human-derived genetic sequences for the pro-apoptotic protein and regulatory elements, making the suicide switch system immunologically compatible with human recipients. This reduces immune recognition and adverse reactions while maintaining the safety function.
Solution Approach 2:
The patent utilizes parameter changes by controlling protein expression levels through inducer concentration, allowing the system to remain dormant at low concentrations (avoiding immune detection) and activate fully at therapeutic concentrations, thus minimizing immune response while ensuring safety when needed.
3Adaptability or versatility
If conventional inducer systems are used for transgene expression control, then gene expression can be modulated, but the induction is slow and not highly specific
Solution Approach 1:
The patent implements dynamics by using an inducer system that allows rapid, reversible, and titratable control of pro-apoptotic protein expression. The system can be quickly activated or deactivated by adjusting inducer concentration, enabling fast response times suitable for emergency safety interventions while maintaining versatile expression modulation.
4Reliability
If a suicide switch system is introduced into CAR T-cells or stem cells, then safety is improved, but the ease of operation and reversibility are reduced
Solution Approach 1:
The patent employs periodic action by using pulsatile or intermittent inducer administration that allows reversible activation of the suicide switch. The system can be toggled on and off by periodic inducer dosing, maintaining ease of operation while ensuring safety through controlled, reversible activation rather than permanent activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise, dose-dependent, and rapid induction or shutdown of gene expression, minimizing immune response and adverse effects, thus enhancing the safety and applicability of gene therapy and cellular therapies.
Implementation Method 1
a regulatory polynucleotide comprising a minimal promoter and at least one AARE (amino acid response element) nucleic acid, said regulatory polynucleotide being activated in an individual upon consumption of a diet deficient in at least one essential amino acid
Data Source
AI summary
A nucleic acid for the controlled expression of a nucleic acid encoding a pro-apoptotic protein in an individual, including: a regulatory polynucleotide including a minimal promoter and at least one AARE (amino acid response element) nucleic acid, the regulatory polynucleotide being activated in an individual upon consumption of a diet deficient in at least one essential amino acid; and a nucleic acid encoding a pro-apoptotic protein, which is placed under the control of the regulatory polynucleotide.